Jeffrey Yoshida, M.D., is program director of urologic oncology at Hoag
Family Cancer Institute and the Benjamin & Carmela Du Endowed Chair
in Urologic Oncology. As program director, he plays a key role in the
growth of site-specific programs for urologic malignancies, which include
prostate, kidney, bladder and testicular cancers.
Dr. Yoshida is an expert in robotic surgery, having performed over 3,000
surgeries to date. He has extensive experience in robotic-assisted radical
prostatectomy (prostate removal), radical nephrectomy (kidney removal)
and partial nephrectomy. With his knowledge and experience in robotic
surgery, Dr. Yoshida brought robotic surgery to Hoag in 2008 and continues
to expand Hoag’s capabilities in minimally invasive robotic surgery.
Dr. Yoshida has a special interest in prostate cancer and has focused
on the development of a comprehensive, multidisciplinary prostate cancer
program. Under his leadership, Hoag participated in the institution’s
first vaccine clinical trial for low-risk prostate cancer. He also started
a prostate cancer early detection program for high-risk men as well as
a state-of-the-art active surveillance program for low-risk cancers. He
chairs the multidisciplinary prostate/urologic oncology case conferences
that are held once a month at Hoag Family Cancer Institute.
Dr. Yoshida is board-certified in urology and has practiced as a urologic
oncologist since 2004. He received his undergraduate degree in biology
from Pacific Union College and earned his medical degree from Loma Linda
University. He completed an internship in general surgery at Harbor-UCLA
and a residency in urology at Loma Linda University. Dr. Yoshida then
completed a fellowship in urologic oncology/robotic surgery at City of
Hope Medical Center. While at City of Hope, he served as assistant clinical
professor in the department of urologic oncology and also held a surgical
leadership role in the kidney cancer program.
Learn more about
Hoag Urologic Oncology Physcians